2015 ACVIM Forum Research Abstract Program

Daily 7.5 mg TM resulted in significantly more food consumed than placebo at 2, 4, 6 and 10 hours (P < 0.0001). Gel concentrations varied by 35-97% of target dose. Grapiprant is a new analgesic that selectively blocks the EP4 receptor of prostaglandin E2 and which may be useful in the treatment of osteoarthritis in dogs and cats. The objective of this study was to evaluate the feline safety and toxicokinetic profiles of grapiprant. Twenty four domestic short-hair cats were randomly assigned to receive either placebo or 3, 9, or 15 mg/kg grapiprant in a capsule formulation (three males and three females per group) once daily for 28 days; all cats received their assigned medications as per protocol. Food consumption and behavior were observed daily, body weight measured weekly, and clinical pathology analyses on blood run on 14, and 25 , and urinalysis run on Days -7, and 25. Serial blood samples for toxicokinetic analyses were obtained following the Day 0 and Day 27 doses. Full necropsies and histopathological evaluations were performed following humane euthanasia on Day 28.